Syndax has entered into a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo.

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 ...

Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Royalty Pharma (RPRX) and Syndax Pharmaceuticals (SNDX) announced that Royalty Pharma has entered into a $350M synthetic royalty funding ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Mexican-American Pablo Legorreta founded Royalty Pharma, which provides funding to pharmaceutical developers in exchange for ...

GRAIL, Inc. , a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and ...

In the worst-case scenario, an unfavourable judgment would prevent Sun Pharma from launching Leqselvi until the patent expires, delaying its market entry.

It has been over two years since my previous Halozyme (NASDAQ:HALO) article, where I discussed Halozyme's acquisition of Antares Pharma for roughly $960M ... Phesgo helped pull in $155M in royalty ...